Cargando…

Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines

The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements which are either unnecessary for effective gene delivery (e.g. bacterial origins of replic...

Descripción completa

Detalles Bibliográficos
Autores principales: Walters, Adam A., Kinnear, Ekaterina, Shattock, Robin J., McDonald, Jacqueline U., Caproni, Lisa J., Porter, Neil, Tregoning, John S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082409/
https://www.ncbi.nlm.nih.gov/pubmed/24830436
http://dx.doi.org/10.1038/gt.2014.37
_version_ 1782324253325000704
author Walters, Adam A.
Kinnear, Ekaterina
Shattock, Robin J.
McDonald, Jacqueline U.
Caproni, Lisa J.
Porter, Neil
Tregoning, John S.
author_facet Walters, Adam A.
Kinnear, Ekaterina
Shattock, Robin J.
McDonald, Jacqueline U.
Caproni, Lisa J.
Porter, Neil
Tregoning, John S.
author_sort Walters, Adam A.
collection PubMed
description The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements which are either unnecessary for effective gene delivery (e.g. bacterial origins of replication) or undesirable (e.g. antibiotic resistance genes). Removing these elements may improve the safety profile of DNA for the delivery of vaccines. Here we describe a novel, double-stranded, linear DNA construct produced by an enzymatic process that solely encodes an antigen expression cassette, comprising antigen, promoter, polyA tail and telomeric ends. We compared these constructs (called ‘Doggybones’ because of their shape) with conventional plasmid DNA. Using luciferase-expressing constructs, we demonstrated that expression levels were equivalent between Doggybones and plasmids both in vitro and in vivo. When mice were immunized with DNA constructs expressing the HIV envelope protein gp140, equivalent humoral and cellular responses were induced. Immunizations with either construct type expressing haemagluttinin were protective against H1N1 influenza challenge. This is the first example of an effective DNA vaccine which can be produced on a large scale by enzymatic processes.
format Online
Article
Text
id pubmed-4082409
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-40824092015-01-01 Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines Walters, Adam A. Kinnear, Ekaterina Shattock, Robin J. McDonald, Jacqueline U. Caproni, Lisa J. Porter, Neil Tregoning, John S. Gene Ther Article The use of DNA to deliver vaccine antigens offers many advantages, including ease of manufacture and cost. However, most DNA vaccines are plasmids and must be grown in bacterial culture, necessitating elements which are either unnecessary for effective gene delivery (e.g. bacterial origins of replication) or undesirable (e.g. antibiotic resistance genes). Removing these elements may improve the safety profile of DNA for the delivery of vaccines. Here we describe a novel, double-stranded, linear DNA construct produced by an enzymatic process that solely encodes an antigen expression cassette, comprising antigen, promoter, polyA tail and telomeric ends. We compared these constructs (called ‘Doggybones’ because of their shape) with conventional plasmid DNA. Using luciferase-expressing constructs, we demonstrated that expression levels were equivalent between Doggybones and plasmids both in vitro and in vivo. When mice were immunized with DNA constructs expressing the HIV envelope protein gp140, equivalent humoral and cellular responses were induced. Immunizations with either construct type expressing haemagluttinin were protective against H1N1 influenza challenge. This is the first example of an effective DNA vaccine which can be produced on a large scale by enzymatic processes. 2014-05-15 2014-07 /pmc/articles/PMC4082409/ /pubmed/24830436 http://dx.doi.org/10.1038/gt.2014.37 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Walters, Adam A.
Kinnear, Ekaterina
Shattock, Robin J.
McDonald, Jacqueline U.
Caproni, Lisa J.
Porter, Neil
Tregoning, John S.
Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
title Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
title_full Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
title_fullStr Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
title_full_unstemmed Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
title_short Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines
title_sort comparative analysis of enzymatically produced novel linear dna constructs with plasmids for use as dna vaccines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082409/
https://www.ncbi.nlm.nih.gov/pubmed/24830436
http://dx.doi.org/10.1038/gt.2014.37
work_keys_str_mv AT waltersadama comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines
AT kinnearekaterina comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines
AT shattockrobinj comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines
AT mcdonaldjacquelineu comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines
AT capronilisaj comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines
AT porterneil comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines
AT tregoningjohns comparativeanalysisofenzymaticallyproducednovellineardnaconstructswithplasmidsforuseasdnavaccines